The 3D discovery and safety platform will enable pharmaceutical companies to rapidly screen multiple combinations of drugs at different doses.
FREMONT, CA: The pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology, InSphero, recently launched its 3D InSight Human Liver Disease Discovery Platform. The drug discovery and safety testing platform is designed for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
The platform is engineered to accommodate all human liver cell types and inducers required for the replication progression of NASH in patients, including scarring and inflammation of the liver. The advanced preclinical discovery platform offers scalable in vitro drug efficacy assessment, screening, combinatorial testing, and the study of complex NASH pathophysiology.
InSphero specializes in liver toxicology, metabolic diseases such as T1 and T2 diabetes and NAFLD & NASH liver disease, and oncology, including immune-oncology and PDX models. The 3D InSight Discovery and Safety Platforms are bolstered by the Akura Technology, which includes 96 and 384-well plate formats and the Akura Flow organ-on-a-chip system to empower innovation through the different phases of drug development. The company collaborates with pharmaceutical and biotechnology researchers to facilitate enhanced decision-making. Major pharmaceutical companies across the world leverage the precisely engineered suite of 3D InSight human tissue platforms to improve the efficiency in drug discovery and safety testing.
The lack of predictive in vitro models that assess the complex mechanisms of disease initiation and progression in patients has impeded the development of novel therapeutics for NASH. However, InSphero aims to fill that gap with its 3D InSight Human Liver Disease Discovery Platform for NAFLD and NASH by facilitating a seamless screening of drug candidates.
NASH is a severe form of the group of chronic conditions caused by the accumulation of excess fat in liver cells. It is characterized by inflammation and fibrosis and can progress asymptotically to adverse disease stages such as advanced liver fibrosis, cirrhosis, and cancer. NASH is related to the increasing epidemic of obesity and type 2 diabetes. Its prevalence is proliferating rapidly, affecting over 10 percent of the adult population in the west. It is predicted to be the main cause of liver transplants in the United States by the year 2020.
The modeling of all elements of the human disease has been challenging in the therapeutic drug discovery sector. Drug screens with animal models of NASH not only take long periods, but they also cannot reflect the effectiveness of the drug on humans. However, the InSphero platform will allow rapid screening of multiple combinations of drugs at different doses.